» Articles » PMID: 24138801

¹H NMR-based Metabolic Profiling of Human Rectal Cancer Tissue

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2013 Oct 22
PMID 24138801
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Rectal cancer is one of the most prevalent tumor types. Understanding the metabolic profile of rectal cancer is important for developing therapeutic approaches and molecular diagnosis.

Methods: Here, we report a metabonomics profiling of tissue samples on a large cohort of human rectal cancer subjects (n = 127) and normal controls (n = 43) using 1H nuclear magnetic resonance (1H NMR) based metabonomics assay, which is a highly sensitive and non-destructive method for the biomarker identification in biological systems. Principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and orthogonal projection to latent structure with discriminant analysis (OPLS-DA) were applied to analyze the 1H-NMR profiling data to identify the distinguishing metabolites of rectal cancer.

Results: Excellent separation was obtained and distinguishing metabolites were observed among the different stages of rectal cancer tissues (stage I = 35; stage II = 37; stage III = 37 and stage IV = 18) and normal controls. A total of 38 differential metabolites were identified, 16 of which were closely correlated with the stage of rectal cancer. The up-regulation of 10 metabolites, including lactate, threonine, acetate, glutathione, uracil, succinate, serine, formate, lysine and tyrosine, were detected in the cancer tissues. On the other hand, 6 metabolites, including myo-inositol, taurine, phosphocreatine, creatine, betaine and dimethylglycine were decreased in cancer tissues. These modified metabolites revealed disturbance of energy, amino acids, ketone body and choline metabolism, which may be correlated with the progression of human rectal cancer.

Conclusion: Our findings firstly identify the distinguishing metabolites in different stages of rectal cancer tissues, indicating possibility of the attribution of metabolites disturbance to the progression of rectal cancer. The altered metabolites may be as potential biomarkers, which would provide a promising molecular diagnostic approach for clinical diagnosis of human rectal cancer. The role and underlying mechanism of metabolites in rectal cancer progression are worth being further investigated.

Citing Articles

Polyp and tumor microenvironment reprogramming in colorectal cancer: insights from mucosal bacteriome and metabolite crosstalk.

Feizi H, Kafil H, Plotnikov A, Kataev V, Balkin A, Filonchikova E Ann Clin Microbiol Antimicrob. 2025; 24(1):9.

PMID: 39881353 PMC: 11780822. DOI: 10.1186/s12941-025-00777-9.


The Potential of Metabolomics in Colorectal Cancer Prognosis.

Fu C, Liu X, Wang L, Hang D Metabolites. 2024; 14(12).

PMID: 39728489 PMC: 11677167. DOI: 10.3390/metabo14120708.


Systematic Review and Meta-Analysis: Taurine and Its Association With Colorectal Carcinoma.

Sinha A, Griffith L, Acharjee A Cancer Med. 2024; 13(23):e70424.

PMID: 39632512 PMC: 11617591. DOI: 10.1002/cam4.70424.


NMR-based metabolomics combined with metabolic pathway analysis reveals metabolic heterogeneity of colorectal cancer tissue at different anatomical locations and stages.

Cai R, Ke L, Zhao Y, Zhao J, Zhang H, Zheng P Int J Cancer. 2024; 156(8):1644-1655.

PMID: 39629979 PMC: 11826128. DOI: 10.1002/ijc.35273.


Hypoxia-induced cysteine metabolism reprogramming is crucial for the tumorigenesis of colorectal cancer.

Lin Z, Yang S, Qiu Q, Cui G, Zhang Y, Yao M Redox Biol. 2024; 75:103286.

PMID: 39079386 PMC: 11340627. DOI: 10.1016/j.redox.2024.103286.


References
1.
Davies N, Wilson M, Harris L, Natarajan K, Lateef S, Macpherson L . Identification and characterisation of childhood cerebellar tumours by in vivo proton MRS. NMR Biomed. 2008; 21(8):908-18. DOI: 10.1002/nbm.1283. View

2.
Shimazu T, Hirschey M, Newman J, He W, Shirakawa K, Le Moan N . Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2012; 339(6116):211-4. PMC: 3735349. DOI: 10.1126/science.1227166. View

3.
Asiago V, Alvarado L, Shanaiah N, Gowda G, Owusu-Sarfo K, Ballas R . Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010; 70(21):8309-18. PMC: 2995269. DOI: 10.1158/0008-5472.CAN-10-1319. View

4.
Beckonert O, Keun H, Ebbels T, Bundy J, Holmes E, Lindon J . Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007; 2(11):2692-703. DOI: 10.1038/nprot.2007.376. View

5.
Lehnhardt F, Bock C, Rohn G, Ernestus R, Hoehn M . Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed. 2005; 18(6):371-82. DOI: 10.1002/nbm.968. View